Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2 clinical trial

20253 citationsJournal Articlehybrid Open Access

Authors

Domenica Lorusso · Agostino Gemelli University Polyclinic

Ana Oaknin · Vall d'Hebron Hospital Universitari

Giuliano Santos Borges

Fernanda Damian · Centro de Pesquisas Oncológicas

Nelleke Ottevanger · Radboud University Nijmegen

Toon Van Gorp · The European Academy of Gynaecological Surgery

Carlos Eduardo Paiva · Hospital de Câncer de Barretos

Abstract

Cemiplimab+peltopepimut-S vaccine provides similar benefits to cemiplimab monotherapy; patients with higher PD-L1 expression in tumor cells may be more likely to benefit from treatment.

Topics & Keywords

Cervical Cancer and HPV Research Immunotherapy and Immune Responses Cancer Immunotherapy and Biomarkers

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Gynecologic Oncology

Volume 196, pp. 28-35

DOI: 10.1016/j.ygyno.2025.03.019

Field-Weighted Citation Impact: 4.23